BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31449347)

  • 1. Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model.
    Xu H; Muise ES; Javaid S; Chen L; Cristescu R; Mansueto MS; Follmer N; Cho J; Kerr K; Altura R; Machacek M; Nicholson B; Addona G; Kariv I; Chen H
    J Cell Mol Med; 2019 Oct; 23(10):7063-7077. PubMed ID: 31449347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
    Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
    Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
    Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
    J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
    Bhise NS; Elsayed AH; Cao X; Pounds S; Lamba JK
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 31022985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.
    Lueck SC; Russ AC; Botzenhardt U; Schlenk RF; Zobel K; Deshayes K; Vucic D; Döhner H; Döhner K; Fulda S; Bullinger L
    Oncotarget; 2016 Aug; 7(31):49539-49551. PubMed ID: 27385100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
    Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
    Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
    Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
    PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications.
    Chen F; Wu X; Niculite C; Gilca M; Petrusca D; Rogozea A; Rice S; Guo B; Griffin S; Calin GA; Boswell HS; Konig H
    J Cell Mol Med; 2020 Jul; 24(13):7378-7392. PubMed ID: 32450611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
    Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
    Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.
    Kuett A; Rieger C; Perathoner D; Herold T; Wagner M; Sironi S; Sotlar K; Horny HP; Deniffel C; Drolle H; Fiegl M
    Sci Rep; 2015 Dec; 5():18411. PubMed ID: 26674118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia.
    Sun H; Ren Y; Zhou X; Chen Q; Liu Y; Zhu C; Ruan Y; Ruan H; Tong H; Ying S; Lin P
    Technol Cancer Res Treat; 2023; 22():15330338231207765. PubMed ID: 37872685
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
    Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
    Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
    Lamba JK; Pounds S; Cao X; Crews KR; Cogle CR; Bhise N; Raimondi SC; Downing JR; Baker SD; Ribeiro RC; Rubnitz JE
    Leuk Lymphoma; 2016; 57(4):909-20. PubMed ID: 26366682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
    Tanaka M
    Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.
    Houshmand M; Soleimani M; Atashi A; Saglio G; Abdollahi M; Nikougoftar Zarif M
    Tissue Eng Part C Methods; 2017 Feb; 23(2):72-85. PubMed ID: 28007011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.